SGLT2 Inhibitors After Acute MI in Non-Diabetics
SGLT2 inhibitors are NOT currently indicated for routine use in non-diabetic patients immediately after acute myocardial infarction, but should be strongly considered if heart failure with reduced ejection fraction (LVEF ≤40%) develops post-MI.
Primary Indication Framework
The evidence clearly distinguishes between two clinical scenarios:
1. Post-MI Without Heart Failure (Non-Diabetic)
Current guidelines do not support routine SGLT2 inhibitor initiation in non-diabetic patients after acute MI who do not have heart failure. The 2023 ACC/AHA Chronic Coronary Disease guidelines 1 and the 2025 ACC/AHA ACS guidelines 2 make no Class I recommendation for SGLT2 inhibitors in this population.
Key limitation: While recent meta-analyses 3, 4, 5, 6 suggest potential benefits in reducing heart failure hospitalization and improving LVEF in non-diabetic post-MI patients, these findings are predominantly from observational studies and small RCTs. The most recent 2026 meta-analysis 3 showed reduced first HF hospitalization (RR: 0.74, p=0.02) and improved LVEF, but no significant reduction in all-cause mortality in the composite endpoint. Another 2026 meta-analysis 6 found benefits were "mainly driven by observational studies" with RCTs showing neutral results.
2. Post-MI With Heart Failure Development (Non-Diabetic)
If HFrEF (LVEF ≤40%) develops after MI, SGLT2 inhibitors are strongly recommended regardless of diabetes status.
The Canadian Heart Failure guidelines 7 provide a Strong Recommendation with High-Quality Evidence: SGLT2 inhibitors (dapagliflozin or empagliflozin) should be used in patients with HFrEF, with or without concomitant type 2 diabetes, to improve symptoms, quality of life, and reduce risk of HF hospitalization and cardiovascular mortality.
The 2023 ACC/AHA guidelines 1 similarly state: "In patients with CCD and heart failure with LVEF ≤40%, use of an SGLT2 inhibitor is recommended to reduce the risk of cardiovascular death and heart failure hospitalization and to improve QOL, irrespective of diabetes status (COR 1)."
Clinical Decision Algorithm
Step 1: Assess for heart failure post-MI
- Obtain echocardiogram to determine LVEF
- Evaluate for signs/symptoms of heart failure
Step 2: If LVEF ≤40% or heart failure present:
- Initiate SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) 7, 8
- This is a Class I recommendation regardless of diabetes status
- Start early in disease course alongside other guideline-directed medical therapy 7
Step 3: If LVEF >40% and no heart failure:
- Do not routinely initiate SGLT2 inhibitor in non-diabetic patients
- Focus on standard post-MI therapies (antiplatelet agents, statins, beta-blockers, ACE inhibitors/ARBs)
- Monitor for heart failure development
Step 4: If LVEF 41-50% with heart failure symptoms:
- SGLT2 inhibitor can be beneficial (COR 2a) 1
- Consider initiation based on individual risk factors
Evidence Quality Considerations
Strong evidence (HFrEF): The DAPA-HF and EMPEROR-Reduced trials 7, 9 demonstrated that approximately 58% of participants did not have diabetes, with nearly identical benefit (HR 0.73 in non-diabetics vs 0.75 in diabetics for the primary endpoint) 9. This represents high-quality RCT evidence.
Weak evidence (post-MI without HF): The 2026 PRESTIGE-AMI trial 10—the most recent high-quality RCT—showed empagliflozin did not reduce infarct size or facilitate reverse LV remodeling at 6 months in high-risk post-MI patients. This contradicts earlier observational data and smaller trials.
Important Caveats
Contraindications and precautions:
- eGFR <30 mL/min/1.73 m² (dapagliflozin contraindicated; empagliflozin not recommended) 7, 11
- eGFR <20 mL/min/1.73 m² excluded from major trials 7
- Type 1 diabetes (contraindicated) 7
- Stop ≥3 days before CABG surgery due to ketoacidosis risk 2
Common adverse effects:
- Genital mycotic infections (10-15% in women) 7
- Temporary eGFR reduction up to 15% (resolves in 1-3 months) 7
- Increased monitoring needed for acute kidney injury risk 7
Timing considerations: The 2025 ACS guidelines 2 acknowledge cardiovascular benefits are "well documented in stable patients with ASCVD" but do not recommend routine early initiation post-ACS in non-diabetic patients without heart failure.
Bottom Line
For non-diabetic patients after acute MI: Wait and assess for heart failure development. If HFrEF emerges (LVEF ≤40%), immediately initiate SGLT2 inhibitor as foundational therapy 7, 8. Without heart failure, current guideline-level evidence does not support routine use, despite promising but inconsistent research data. The divergence between observational studies showing benefit and the neutral 2026 PRESTIGE-AMI RCT 10 underscores the need for ongoing large-scale trials before expanding indications.